{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:48:19Z","timestamp":1760100499141},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.critrevonc.2012.03.005","type":"journal-article","created":{"date-parts":[[2012,4,8]],"date-time":"2012-04-08T00:30:33Z","timestamp":1333845033000},"page":"287-299","source":"Crossref","is-referenced-by-count":4,"title":["The expanding options for front-line treatment in patients with newly diagnosed CML"],"prefix":"10.1016","volume":"84","author":[{"given":"Javier","family":"Pinilla-Ibarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2012.03.005_bib0005","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia v.2.2012. Available at: nccn.org."},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0015","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0020","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0025","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12185-008-0092-5","article-title":"Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation","volume":"88","author":"Akahane","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0145-2126(01)00095-9","article-title":"Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation","volume":"26","author":"Kearney","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0040","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"Robin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.bmt.1701729","article-title":"Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation","volume":"23","author":"Yong","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/107327480901600207","article-title":"Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities","volume":"16","author":"Fernandez","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0055","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/clpt.2009.297","article-title":"Targeted cancer therapies in the twenty-first century: lessons from imatinib","volume":"87","author":"Stegmeier","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11899-010-0045-y","article-title":"Tyrosine kinase inhibitors: the first decade","volume":"5","author":"Agrawal","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0075","unstructured":"Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012, January."},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0085","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0090","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0095","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0110","article-title":"Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase","author":"Rosti","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MOH.0b013e3283366bcb","article-title":"Managing imatinib resistance in chronic myeloid leukaemia","volume":"17","author":"Osborn","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0120","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","article-title":"Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia","volume":"25","author":"White","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0125","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0130","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0135","unstructured":"Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011, November."},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0140","unstructured":"Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2011, October."},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0145","first-page":"233","article-title":"Development and targeted use of nilotinib in chronic myeloid leukemia","volume":"2","author":"Fava","year":"2009","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0150","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","article-title":"Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib","volume":"18","author":"Manley","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0155","article-title":"Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions","author":"Valent","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.V116.21.359.359","article-title":"Excellent outcomes at 3 years with nilotinib 800mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML WP Clinical Trial","volume":"116","author":"Rosti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0170","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0175","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/cc.10.10.15518","article-title":"Explaining the in vitro and in vivo differences in leukemia therapy","volume":"10","author":"Lenaerts","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0180","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood.V116.21.3431.3431","article-title":"Nilotinib lowers the incidence of BCR-ABL mutations and improves the molecular response kinetics compared with imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia (CML)","volume":"116","author":"Hochhaus","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0185","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood.V116.21.2291.2291","article-title":"Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd","volume":"116","author":"Larson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0190","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0195","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0200","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0205","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.LBA-6.LBA-6","article-title":"A randomized phase II trial of dasatinib 100mg vs imatinib 400mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup Trial","volume":"116","author":"Radich","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0210","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0215","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in good-risk chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0220","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"2009","author":"Bixby","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0230","doi-asserted-by":"crossref","first-page":"RRN1204","DOI":"10.1371\/currents.RRN1204","article-title":"BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"2","author":"Terasawa","year":"2010","journal-title":"PLoS Curr"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0235","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0240","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1200\/jco.2010.28.15_suppl.6133","article-title":"Symptom burden in chronic myeloid leukemia (CML)","volume":"28","author":"Williams","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0245","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0250","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0260","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0265","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0270","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0275","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.V114.22.337.337","volume":"114","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0280","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0285","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2009.016766","article-title":"Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia","volume":"95","author":"Deenik","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0295","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2006.06.002","article-title":"The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with imatinib mesylate predicts for prolonged response at 6 years","volume":"37","author":"Piazza","year":"2006","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0300","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0305","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.critrevonc.2010.07.003","article-title":"The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era","volume":"79","author":"Breccia","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0310","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0315","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0320","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0325","doi-asserted-by":"crossref","unstructured":"Hanfstein B, M\u00fcller MC, Erben P, et al. for The SAKK, for The German CML Study Group. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients \u2013 a follow-up analysis of the German CML Study IV. In: ASH Annual Meeting Abstracts. Blood 2011;118:783.","DOI":"10.1182\/blood.V118.21.783.783"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0330","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood.V118.21.3783.3783","article-title":"Complete cytogenetic response after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia","volume":"118","author":"Latagliata","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0335","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.V118.21.1684.1684","article-title":"The month three major molecular response in chronic phase chronic myeloid leukemia on imatinib400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0340","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood.V118.21.2767.2767","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0345","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V118.21.785.785","article-title":"The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy","volume":"118","author":"Marin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0350","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/asheducation-2009.1.477","article-title":"Monitoring disease response to tyrosine kinase inhibitor therapy in CML","author":"Hughes","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0355","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0360","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, Multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0365","series-title":"ASH Annual Meeting Abstracts, vol. 110","first-page":"473","article-title":"Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL","author":"Gambacorti-Passerini","year":"2007"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0370","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0375","series-title":"ASH Annual Meeting Abstracts, vol. 116","first-page":"210","article-title":"A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings","author":"Cortes","year":"2010"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0380","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.V118.21.601.601","article-title":"A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0385","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0390","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358) \u2013 a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor","volume":"184","author":"Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0395","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0400","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1200\/jco.2010.28.15_suppl.6509","article-title":"Safety and efficacy of bosutinib in patients with AP and BP CML and Ph+ ALL following resistance\/intolerance to imatinib and other TKIs: update from study SKI-200","volume":"28","author":"Gambacorti-Passerini","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2012.03.005_bib0405","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812000716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812000716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T15:01:44Z","timestamp":1593961304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842812000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1040842812000716"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2012.03.005","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}